Iclaprim

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

Abstract

Iclaprim (previously known as AR-100 and Ro 48-2622) is a new member of the diaminopyrimidine class of antimicrobials, to which trimethoprim also belongs. As with trimethoprim, iclaprim is an inhibitor of bacterial dihydrofolate reductase (DHFR), an enzyme in the folate synthesis pathway. The two potential advantages of iclaprim compared with trimethoprim are an increased affinity for bacterial DHFR, particularly in Gram-positive bacteria, and activity against trimethoprim-resistant organisms. Iclaprim is therefore a potentially interesting new agent for the treatment of multiresistant Gram-positive infections.

Original languageEnglish
Title of host publicationKucers the Use of Antibiotics
Subtitle of host publicationA Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
EditorsM. Lindsay Grayson
PublisherCRC Press
Pages1775-1783
Number of pages9
Edition7th
ISBN (Electronic)9781498747967
ISBN (Print)9781498747950
Publication statusPublished - 1 Jan 2017

Cite this

Stewardson, A., & Lindsay Grayson, M. (2017). Iclaprim. In M. L. Grayson (Ed.), Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (7th ed., pp. 1775-1783). CRC Press.
Stewardson, Andrew ; Lindsay Grayson, M. / Iclaprim. Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. editor / M. Lindsay Grayson. 7th . ed. CRC Press, 2017. pp. 1775-1783
@inbook{d208974855d94c1280c1d2096228c4bb,
title = "Iclaprim",
abstract = "Iclaprim (previously known as AR-100 and Ro 48-2622) is a new member of the diaminopyrimidine class of antimicrobials, to which trimethoprim also belongs. As with trimethoprim, iclaprim is an inhibitor of bacterial dihydrofolate reductase (DHFR), an enzyme in the folate synthesis pathway. The two potential advantages of iclaprim compared with trimethoprim are an increased affinity for bacterial DHFR, particularly in Gram-positive bacteria, and activity against trimethoprim-resistant organisms. Iclaprim is therefore a potentially interesting new agent for the treatment of multiresistant Gram-positive infections.",
author = "Andrew Stewardson and {Lindsay Grayson}, M.",
year = "2017",
month = "1",
day = "1",
language = "English",
isbn = "9781498747950",
pages = "1775--1783",
editor = "Grayson, {M. Lindsay }",
booktitle = "Kucers the Use of Antibiotics",
publisher = "CRC Press",
address = "Australia",
edition = "7th",

}

Stewardson, A & Lindsay Grayson, M 2017, Iclaprim. in ML Grayson (ed.), Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. 7th edn, CRC Press, pp. 1775-1783.

Iclaprim. / Stewardson, Andrew; Lindsay Grayson, M.

Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. ed. / M. Lindsay Grayson. 7th . ed. CRC Press, 2017. p. 1775-1783.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

TY - CHAP

T1 - Iclaprim

AU - Stewardson, Andrew

AU - Lindsay Grayson, M.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Iclaprim (previously known as AR-100 and Ro 48-2622) is a new member of the diaminopyrimidine class of antimicrobials, to which trimethoprim also belongs. As with trimethoprim, iclaprim is an inhibitor of bacterial dihydrofolate reductase (DHFR), an enzyme in the folate synthesis pathway. The two potential advantages of iclaprim compared with trimethoprim are an increased affinity for bacterial DHFR, particularly in Gram-positive bacteria, and activity against trimethoprim-resistant organisms. Iclaprim is therefore a potentially interesting new agent for the treatment of multiresistant Gram-positive infections.

AB - Iclaprim (previously known as AR-100 and Ro 48-2622) is a new member of the diaminopyrimidine class of antimicrobials, to which trimethoprim also belongs. As with trimethoprim, iclaprim is an inhibitor of bacterial dihydrofolate reductase (DHFR), an enzyme in the folate synthesis pathway. The two potential advantages of iclaprim compared with trimethoprim are an increased affinity for bacterial DHFR, particularly in Gram-positive bacteria, and activity against trimethoprim-resistant organisms. Iclaprim is therefore a potentially interesting new agent for the treatment of multiresistant Gram-positive infections.

UR - http://www.scopus.com/inward/record.url?scp=85056681059&partnerID=8YFLogxK

M3 - Chapter (Book)

SN - 9781498747950

SP - 1775

EP - 1783

BT - Kucers the Use of Antibiotics

A2 - Grayson, M. Lindsay

PB - CRC Press

ER -

Stewardson A, Lindsay Grayson M. Iclaprim. In Grayson ML, editor, Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. 7th ed. CRC Press. 2017. p. 1775-1783